Russ Conroy

A new drug combination, talquetamab and teclistamab, shows promising results in treating patients with heavily pretreated multiple myeloma, with high response rates and durable responses.

The ADRIATIC trial found that consolidation therapy with durvalumab improved progression-free survival and overall survival in patients with limited-stage small cell lung cancer, regardless of prior prophylactic cranial irradiation or concurrent chemoradiotherapy use.

Response outcomes with liso-cel were consistent regardless of the presence of high-risk disease features in patients with relapsed/refractory chronic lymphocytic leukemia.

An increased likelihood of response was also observed in patients who received no more than 3 lines of therapy prior to liso-cel in the TRANSCEND CLL 004 trial.

Prophylactic treatment with tocilizumab shows promise for reducing a serious adverse effect in multiple myeloma treatment.

Data from DREAMM-7 showed comparable patient-reported outcomes between belantamab/bortezomib/dexamethasone and daratumumab/bortezomib/dexamethasone in relapsed/refractory multiple myeloma.

PolyPEPI1018 given in combination with atezolizumab showed tolerability and induced immune responses in patients with relapsed/refractory microsatellite-stable metastatic colorectal cancer.

Belantamab mafodotin in combination with other therapies shows promise for patients with multiple myeloma following the first relapse.

Administering high-intensity focused ultrasound could be a noninferior treatment option for patients with localized prostate cancer, according to a prospective trial.

Ex vivo generation of CD3-positive, CD56-positive Natural Killer-Like (NKT) with CRX100 was successful in all 7 patients with ovarian cancer in a phase 1 trial.

In the phase 3 LEAP-001, the combination of lenvatinib plus pembrolizumab improved progression-free survival and overall survival among patients with endometrial cancer.

A retrospective study demonstrated the feasibility and efficacy of brexucabtagene autoleucel in treating central nervous system involvement in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Research suggests that combining cabozantinib with atezolizumab could emerge as a promising alternative for individuals facing metastatic castration-resistant prostate cancer that has advanced after novel hormonal therapy.

Results from the phase 3 FRESCO-2 trial substantiate the potential of fruquintinib to offer enhanced survival benefits and improved quality of life for individuals with metastatic colorectal cancer who have undergone prior treatments.

Data from the phase 3 APPLY-PNH trial show comprehensive control of intravascular and extravascular hemolysis with iptacopan in patients with paroxysmal nocturnal hemoglobinuria and persistent anemia.

Real-world evidence from over 2000 patients with chronic lymphocytic leukemia, over half of whom received prior covalent BTK inhibitor, confirmed the efficacy of venetoclax in pretreated patients.

Adding ribociclib to endocrine therapy shows efficacy and tolerability for those with hormone receptor–positive, HER2-negative advanced breast cancer, even in older patients.

Pembrolizumab and mRNA-4157 demonstrated improvements in subgroups of resected melanoma, including those with BRAF-mutated tumors, in the phase 2 KEYNOTE-942 trial.

Progression-free survival in the central nervous system appears to be longer with trastuzumab deruxtecan than with comparator treatment in patients with HER2-positive metastatic breast cancer and brain metastases.

The addition of durvalumab to standard-of-care chemotherapy shows potential to improve downstaging in patients with resectable gastroesophageal junction and gastric cancer, according to findings from the phase 3 MATTERHORN study.

At the SOHO 2023 Annual Meeting, Mohammad Bakri Hammami, MD, spoke about the need to address disparities related to race, sex, and age among patients with primary myelofibrosis to ensure that everyone receives high-quality treatment.

Teclistamab plus talquetamab is the first-ever reported dual-specific bispecific combination in hematologic malignancies, says María-Victoria Mateos, MD, PhD.

Eftilagimod alpha plus pembrolizumab showed an overall response rate of over 25% in patients with metastatic head and neck squamous cell carcinoma treated in the phase 2 TACTI-002 study.

Phase 3 DUO-O study results reveal a promising strategy for patients with HRD-negative advanced ovarian cancer.

Nivolumab and sunitinib combined in the first-line treatment continues to maintain benefit for patients with advanced or metastatic renal cell carcinoma.

New findings from the phase 2 INFINITY trial shows promise for tremelimumab and durvalumab in patients with gastric/GEJ adenocarinoma.

Results from the phase 1b MajesTEC-2 trial showed that teclistamab plus daratumumab and lenalidomide demonstrated potential for deep and durable responses in relapsed or refractory multiple myeloma.